[The antiaggregant activity of the synthetic antioxidant emoxipin].
The action of the synthetic antioxidant aemoxipin, 3-oxypyridime derivative on platelet aggregation was studied in 8 patients with ischemic heart disease and cardialgias. An hour later after an intravenous injection in a dose of 5-10 mg/kg, aemoxipin reduced platelet aggregation by 25% (p < 0.05), inhibited the reaction of "release" and spontaneous platelet aggregation. The same effect of the drug was demonstrated in the aggregation caused by ADP action on platelets preliminarily activated by minimum adrenaline concentrations in a tube. Our results are in agreement with the data of other investigators concerning a direct, non-specific nature of aemoxipin action on cellular membranes.
Stoliarov
V A
VA
Repin
A N
AN
Markov
V A
VA
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000787:Angina Pectoris / Q000097:blood / Q000188:drug therapy; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy; D010847:Picolines / Q000008:administration & dosage / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*
D000975:Antioxidants; D010847:Picolines; D010975:Platelet Aggregation Inhibitors; D000244:Adenosine Diphosphate; C009820:6-methyl-2-ethyl-3-hydroxypyridine
Antiagregatsionnaia aktivnost' sinteticheskogo antioksidanta émoksipina.